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Abstract
Fungal osteomyelitis is a rare, life threatening complication of solid organ transplantation often associated with long term
sequelae. Here we describe the use of a multi-disciplinary management approach including combination antifungal therapy,
surgery and hyperbaric oxygen therapy in the successful management of Aspergillus fumigatus osteomyelitis of the humeral
head in a lung transplant recipient. To our knowledge this is only the third documented case of Aspergillus fumigatus
osteomyelitis in a lung transplant patient and the first involving a patient with no known primary source of aspergillosis.
CASE REPORT
A 26 year old man underwent bilateral sequential lung
transplantation for cystic fibrosis complicated by respiratory
failure. The recipient was seropositive for cytomegalovirus
(CMV). The peri-operative course was complicated by type
1 hypersensitivity to methylprednisolone leading to cardiac
arrest requiring urgent institution of cardiopulmonary bypass
via the groin and re-operation for severe intra-thoracic
haemorrhage. Post-transplant immunosuppression consisted
of cyclosporin (to maintain trough serum levels of 300 – 350
g/l), mycophenolate (1.5g bd) and dexamethasone (1.5mg
daily). Basiliximab (Simulect, Novartis pharmaceuticals)
was administered day 1 and 5 as a cyclosporine sparing
agent given problems with intrapleural haemorrhage and
renal impairment. Due to poor absorption, cyclosporin was
changed to tacrolimus (target serum levels of 10-15g/l) on
day 15 post transplant. Valganciclovir (450mg/day),
nebulised amphotericin B (10mg bd) and
sulfamethoxazole/trimethoprim (twice weekly) were
administered for CMV, fungal and Pneumocystis jiroveci
prophylaxis respectively.
Fourteen days post transplant, fluconazole was commenced
following the isolation of Candida tropicalis from pleural
fluid. An area of left lung consolidation was subsequently
investigated with bronchoscopy. Pseudomonas aeruginosa
and Candida albicans were grown from bronchoalveolar
lavage fluid and transbronchial biopsies revealed organizing
pneumonia, but no evidence of rejection. His treatment
continued with meropenem, ciprofloxacin and fluconazole.
The patient was discharged from hospital seven weeks post
transplant with no further complications except poorly
controlled diabetes mellitus during the follow-up period.
Three months post transplant, the patient presented in status
epilepticus requiring intubation. The blood sugar level was
1.2 mmol/L. Investigation revealed a normal chest x-ray,
mild renal impairment, no leukocytosis and a c-reactive
protein (CRP) of 115 mg/L. A CT Head revealed white
matter hypo-attenuation in the left frontal lobe and a lumbar
puncture was negative for cryptococcal antigen and herpetic
viruses. As the patient was unable to have a MRI head at this
point due to an in-situ portacath, a presumptive diagnosis of
seizures related to hypoglycaemia and reversible posterior
leukoencephalopathy secondary to tacrolimus was made.
The hypoglycaemia was corrected, tacrolimus was switched
back to cyclosporin, systemic blood pressure aggressively
controlled and he was admitted to the intensive care unit.
The patient’s neurological state rapidly improved and he was
extubated. With further clinical history now available, he
reported a one week history of a painful, hot and swollen
right shoulder. Fluid aspirated from the right shoulder grew
Aspergillus fumigatus. Voriconazole and caspofungin were
commenced in combination. A bone scan (Figure 1) showed
increased vascularity and radiotracer uptake in the right
shoulder. No intra-cardiac vegetations were identified on
echocardiogram. A MRI was performed after removal of the
portacath but due to movement artefact, only the head could
be imaged. Three focal areas of increased T2 hyper-intensity
were seen in the frontal lobe, occipital lobe and
frontoparietal region confirming the presumptive diagnosis
of reversible posterior leuoencephalopahy secondary to
tacrolimus toxicity. There were no cerebral abscesses.
Figure 1
FIGURE 1: Bone scan showing increased radiotracer uptake
in the right shoulder
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A progress CT of the shoulder ten days after the initial
presentation suggested infective collections involving the
subscapularis muscle and right posterior glenohumeral head.
There was also a cortical break and associated mixed
lytic/sclerotic changes in the posterior humeral head
confirming septic arthritis and osteomyelitis (Figure 2).
Despite this there was clinical improvement and the CRP
had fallen to 22 mg/L. Voriconazole was changed to
posaconazole due to deranged liver function tests after
thirteen days of therapy.
Figure 2
FIGURE 2: CT of shoulder confirming sclerotic changes of
the posterior humeral head
Twenty days after initial presentation the patient complained
of increased pain and decreased range of movement of the
right shoulder, he became febrile and the CRP increased to
68 mg/L. The radiologic appearance had deteriorated with an
increase in the number and size of locules in the
subscapularis muscle, the development of a glenohumeral
joint effusion, and an air locule in the posterior aspect of the
humeral head (Figure 3). Subsequent MRI of the right
shoulder showed enhancement and oedema throughout the
right humeral head and extending 9.5cm into the proximal
humeral shaft (Figure 4). Cyclosporin was decreased with a
target C2 (2 hour post-dose) level of 300-400 and
intravenous amphotericin was commenced, in addition to the
caspofungin and oral posaconazole. An arthroscopic
washout of the right shoulder was performed and converted
to an open washout with subsequent synovectomy of the
biceps sheath with removal of caseous material.
Figure 3
FIGURE 3: Repeat CT of the right shoulder 20 days after
presentation. Note air locule in posterior humeral head (3A)
and the air locule in the subscapularis muscle (3B)
Figure 4
FIGURE 4: MRI of the shoulder demonstrating significant
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osteomyelitis and oedema
On day 23 the patient commenced daily hyperbaric oxygen
therapy. By day 33 the patient had improved and repeat MRI
at day thirty-five showed radiological improvement. His
recovery was complicated by a lower-respiratory tract
infection for which he received meropenem and
ciprofloxacin. Forty-six days after admission the
amphotericin, caspofungin and meropenem were ceased and
the patient was discharged home to continue the hyperbaric
oxygen therapy (to a total of 40 treatments) and
posaconazole as an outpatient.
Six months after the initial presentation, the patient again
presented with worsening pain in the right shoulder.
Investigation revealed recurrence of osteomyelitis in the
humeral head and he subsequently underwent open
debridement of the humeral head and insertion of
amphotericin cement beads. Posaconazole was changed back
to voriconazole without a significant deterioration in liver
function. The patient made a full recovery with a full range
of movement at the shoulder joint, and normal allograft
function 15 months after initial presentation with Aspergillus
osteomyelitis.
DISCUSSION
Aspergillus osteomyelitis is rare although it is the fourth
most common site of aspergillosis(1). A 2005 review
identified 63 reported cases of Aspergillus osteomyelitis and
joint infections between 1977 and 2003. (1) In immuno-
competent patients osteomyelitis commonly results from the
hematogenous spread of invasive pulmonary aspergillosis. It
is estimated 6%-16% of heart and lung transplant recipients
are treated for invasive pulmonary aspergillosis post-
transplant (2, 5). Interestingly in our patient all routine
bronchoscopy’s pre and post operatively showed no
evidence of pulmonary Aspergillus infection. Risk factors
for invasive aspergillosis after transplantation include; dose
and length of immunosuppressive therapy, presence of
vascular complications, neutropenia, defective phagocytes,
allograft rejection, diabetes, renal failure, malignancy,
bacterial and CMV infections, use of antibiotics, parenteral
nutrition, and dialysis (3).
Infections of bone and joints caused by Aspergillus are
recognised as being difficult to treat and often requiring
prolonged medical therapy. Unfortunately optimal treatment
is yet to be defined and currently is based on a collection of
small case series and single case studies.
Traditionally treatment has focused on Amphotericin B and
surgical debridement. However, single use of Amphotericin
B has fallen out of favour due to its poor bone/joint tissue
penetration and the sub-optimal response of infection when
used as a single agent. Other medical options for treatment
include triazoles: itraconazole, voriconazole, ravuconazole
and posaconazole; flucytosine and caspofungin. Fluconazole
has no activity against Aspergillus, and our patient
developed the disease while on fluconazole. Itraconazole,
voriconazole and posaconazole are known to have good anti-
Aspergillus activity and achieve good bone penetration.
Compared with Amphotericin B (AmB) and itraconazole,
posaconazole has the best in vitro activity against
Aspergillus species (3, 4). Moreover, clinical success has
been demonstrated with posaconazole in the treatment of
invasive aspergillosis in patients in whom AmB or
itraconazole therapy has failed (5). The echinocandin
caspofungin has in vitro activity against Aspergillus, but has
poorer bone penetration. There seems little place for
caspofungin monotherapy to treat Aspergillus osteomyelitis,
however it may have a role as part of combination therapy.
(1) Caspofungin and voriconazole in combination have
previously been examined. Singh et al. compared 40 solid
organ transplant patients who received voriconazole and
caspofungin as primary therapy with a control group of 47
patients who received liposomal amphotericin B. While
there was no overall mortality difference between the two
groups, in patients with renal failure, combination therapy
was shown to be independently associated with improved
survival.(6) In the review of the literature performed by
Kirby et al, the combination of amphotericin B and
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flucytosine resulted in successful treatment in all cases.(1)
Our patient was commenced on voriconazole and
caspofungin combination therapy but later voriconazole was
changed to posaconazole due to deranged liver function
tests. Amphotericin B was later added to the regime,
although there was initial hesitancy because of pre-existing
impaired renal function. In solid organ transplant recipients,
whenever possible, consideration should also be given to
carefully decreasing the degree of immunosuppression as an
adjunct to medical therapy for the treatment of invasive
aspergillosis. Despite lowering the patient’s
immunosuppression he did not develop acute allograft
rejection and graft function remains excellent.
Hyperbaric oxygen (HBO) is claimed to be helpful in
refractory osteomyelitis. The functional definition most
commonly applied to hyperbaric candidates includes failure
to respond to a 4- to 6-week course of appropriate antibiotics
(7). A large number of animal data and in vitro experimental
studies supports the use of HBO in refractory osteomyelitis
(8). Uncontrolled trials of surgery and antibiotics combined
HBO in refractory osteomyelitis in the past have shown
success rates as high as 85% (9). As yet there are no
randomized controlled trials relating to refractory
osteomyelitis. Unfortunately randomized controlled trials
may be difficult to accomplish, given the relative
infrequency of the illness and the varied patient and disease
characteristics. HBO therapy is considered safe when used
according to standard protocols, with oxygen pressures not
exceeding 300 kPa and treatment duration not exceeding 120
minutes (10). Due to rapid pressure changes, adverse effects
include barotrauma to the middle ear, cranial sinuses and, in
rare cases, the teeth or lungs. HBO-related pulmonary
toxicity is thought to be a concern in lung transplant patients
due to pre-existing co-morbidities and increased
susceptibility to toxic pulmonary injury (10). Throughout
treatment our patient’s lung function was stable.
The addition of HBO as an adjunctive therapy significantly
increases the upfront cost of treatment. In complicated cases
of refractory osteomyelitis, however, the long-term expenses
associated with prolonged hospitalization, long courses of
antimicrobial therapy, and additional surgery actually offset
the differences, frequently making HBO cost effective (8)
To our knowledge, this is the first reported case of
osteomyelitis in a solid organ recipient that has included
hyperbaric oxygen therapy in the treatment regime and one
of the few documented cases of aspergillus osteomyelitis
involving a lung transplant patient.
The authors wish to advise that they received no funding
from outside sources and declare no conflict of interest in
presenting this case.
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